Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor has reached a milestone in antibody optimization collaboration agreement with CSL Limited.
Subscribe to our email newsletter
The filing of an investigational new drug application with the FDA for a monoclonal antibody that was optimized using Xencor’s XmAb antibody technology prompted the milestone payment.
Xencor CEO Bassil Dahiyat said, "This milestone payment marks the second that Xencor has received in recent weeks for antibody therapeutics developed by our partners using XmAb technology moving into the clinic, bringing the total number of XmAb antibodies in clinical development to seven."
The cancer drug target and the amount of milestone payment were not disclosed by the companies.
The companies entered into a collaboration agreement in 2009, under which CSL was granted access to Xencor’s XmAb technology platform to enhance the antibody-dependent cell cytotoxicity (ADCC) function of therapeutic antibodies.